Nano mentioned on a Swiss investment site.
“Those who are not afraid of the risk associated with individual stocks in this sector will find what they are looking for at the US investment bank Stifel. Its analysts follow more than 20 smaller European biotechnology companies. Stifel’s experts have been spot on in recent years with their buy recommendations for Abivax, Nanobiotix, Oxford Biomedica, and Synektik. The value of all three stocks has at least doubled. The top performer, Abivax, rose from 5 euros to as much as 102 euros within a year and still has upside potential. Stifel recently raised its price target to 142 euros.
Helsinki-based Nanoform Finland is not a traditional drug developer, but rather a specialized contract development and manufacturing organization (CDMO) service provider, like Lonza or Siegfried. CDMO stands for “Contract Development and Manufacturing Organization”. It focuses on the so-called “nanonization” of active pharmaceutical ingredients (APIs), as 70–90 percent of traditional APIs are not water-soluble and therefore do not meet regulatory approval requirements. Nanoform Finland addresses this challenge by using its proprietary technology to reduce API particles to the nanoscale. This increases surface area, improves solubility, and increases bioavailability. Stifel’s analysts are convinced that Nanoform can achieve its ambitious medium-term targets. The stock price upside potential is over 200 percent.”